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Abstract
The importance of a protein-protein interaction to a signaling pathway can be established by
showing that amino acid mutations that weaken the interaction disrupt signaling, and that
additional mutations that rescue the interaction recover signaling. Identifying rescue mutations,
often referred to as second-site suppressor mutations, controls against scenarios in which the
initial deleterious mutation inactivates the protein or disrupts alternative protein-protein
interactions. Here, we test a structure-based protocol for identifying second-site suppressor
mutations that is based on a strategy previously described by Kortemme and Baker. The molecular
modeling software Rosetta is used to scan an interface for point mutations that are predicted to
weaken binding but can be rescued by mutations on the partner protein. The protocol typically
identifies three types of specificity switches: knob-in-to-hole redesigns, switching hydrophobic
interactions to hydrogen bond interactions, and replacing polar interactions with non-polar
interactions. Computational predictions were tested with two separate protein complexes; the G-
protein Gαi1 bound to the RGS14 GoLoco motif, and UbcH7 bound to the ubiquitin ligase E6AP.
Eight designs were experimentally tested. Swapping a buried hydrophobic residue with a polar
residue dramatically weakened binding affinities. In none of these cases were we able to identify
compensating mutations that returned binding to wild type affinity, highlighting the challenges
inherent in designing buried hydrogen bond networks. The strongest specificity switches were a
knob-in-to-hole design (20-fold) and the replacement of a charge-charge interaction with non-
polar interactions (55-fold). In two cases, specificity was further tuned by including mutations
distant from the initial design.
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Introduction
Defining the role of a protein in a signaling pathway can be challenging because many
proteins interact with multiple upstream and downstream binding partners. Amino acid
mutations that disrupt interactions with one partner often disrupt interactions with several
partners. If there are changes in signaling that accompany a mutation, it is not clear which
protein-protein interaction is responsible. One strategy for identifying the key interactions is
to use a genetic screen to search for suppressor mutations on the binding partners1. Random
mutations are introduced into a genome, a set of proteins or a single protein and screened to
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identify mutations that suppress the initial deleterious mutation. An alternative approach is
to use structure-based molecular modeling. In this case, high resolution structures of the
protein-protein interfaces are used to predict mutations that will weaken binding but then
can be compensated by further mutations on the partner protein2. The potential advantages
of this approach are that it can be quick if the computational predictions are accurate and it
does not require the development of a genetic screen.
Several computational approaches have been used to redesign protein binding specificities3;
4. The methods vary by how much explicit negative design is performed. For instance,
consider a scenario where protein A naturally binds protein B and protein C with equal
affinity and the goal is to redesign protein A so that it binds more tightly to B. One approach
is to perform a sequence optimization simulation that only explicitly optimizes the binding
energy between protein A and B5. This is referred to as positive design, and does not
include explicit calculations of the binding energy between protein A and C. This approach
has been used to successfully redesign the binding specificity of calmodulin for target
peptides6; 7. The redesigned calmodulin maintains wild-type affinity for the target sequence
from smooth muscle myosin light chain kinase, but binds less tightly to a group of other
native binding partners. One advantage of using only positive design is that it is not
necessary to have an accurate structure or model of the undesired interactions. Another
strategy is to simultaneously include both positive and negative design in the design process,
and explicitly optimize the energy gap between the target and undesired interactions8; 9; 10.
This is often referred to as multi-state design. Multi-state design has been used to redesign
binding specificities between coiled-coils and create a heterodimer from the SspB adopter
protein homodimer11. Recently, Grigoryan et al. used large-scale multi-state design
simulations to create sequences that recognize specific members of the Bzip family of
coiled-coils 12. Designs based entirely on positive design did not attain the desired
specificities.
A third strategy for redesigning binding specificities is to separate negative and positive
design into different steps. Kortemme et al. used this approach to design second-site
suppressor mutations2. First, they scanned through a protein-protein interface for mutations
predicted to destabilize the interaction. For each deleterious mutation, a design simulation
was run to determine if compensating mutations could be identified by redesigning
surrounding residues (residues on both sides of the interface were allowed to vary). Using
the interaction between colicin E7 and the immunity protein Im7 as a model system, they
created two designs that exhibited a ~20-fold change in binding specifity. For instance, in
one case wild type E7 bound to mutated Im7 with an affinity of ~300 nM, while redesigned
E7 bound to mutated Im7 with an affinity ~12 nM. Because the affinity of the wild type pair
was too strong to measure, they were not able to determine how the affinity of the
redesigned pair compared to the wild type pair.
Here, we provide further testing of the second-site suppressor strategy for redesigning
protein-protein binding specificities. In particular, we are interested if specificity switches
can be achieved with only one or two mutations on each side of the interface. In general,
redesigns that minimize the number of mutations required for changing binding specificities
will be more attractive for in cell studies as they are less likely to perturb other features of
the protein that may be critical for function. Additionally, redesigns focused on just a few
residues allow more specific feedback as to which types of interactions, for instance
hydrogen bonding versus van der Waals, can be modeled more reliably. We focus on three
types of switches: knob-in-to-hole redesigns, switching hydrophobic interactions to
hydrogen bond interactions, and replacing polar interactions with non-polar interactions.
Predictions were tested with two separate complexes; Gαi1 from the heterotrimeric G-
protein system bound to the RGS14 GoLoco peptide, and the E2, UbcH7, bound to the E3,
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E6AP from the ubiquitin pathway 13; 14. Both interfaces are large (> 2000 Å2), and contain
a mixture of hydrophobic and polar interactions.
Results
Despite having large interfaces, a relatively small number of second-site suppressor designs
were identified for both model systems. For the interaction between Gαi1 and the GoLoco
peptide 84 interface positions were screened, and for the interaction between UbcH7 and
E6AP 44 interface positions were screened. At each residue position, all possible point
mutations, except to cysteine, were tested. For mutations that were predicted to destabilize
binding by more than 0.5 kcal/mol, a second round of simulations was performed to identify
compensating mutations. All residues within 5.5 Å of the point mutation were allowed to
vary, including residues on the same chain as the mutation. The results from the second
round of simulations were filtered to select for rescue mutations that brought binding within
0.3 kcal/mol of the wild type interaction yet filter out mutations that destabilize the
individual protein chains by more than 1 kcal/mol based on the predicted ΔΔGobind,
ΔΔGochainA and ΔGochainB. For UbcH7 and E6AP 16 designs passed the filters (from 360
destabilizing mutations) and for Gαi1 and the GoLoco peptide 24 designs passed the filters
(from 440 destabilizing mutations). From the 40 designs (Tables S.1 and S.2), 4 designs
were selected from each model system (Table 1). Emphasis was placed on selecting design
that represent the three types of specificity switches, designs that represent different regions
of each protein: protein interface, and designs that involved fewer numbers of mutations.
Additionally for the Gαi1/GoLoco complex, designs that mutated residues near the GDP
binding pocket and designs that varied GoLoco Q508 were not considered for experimental
testing. In a previous study to identify affinity enhancing mutations at the Gαi1/GoLoco
interface we found that Rosetta underpredicts favorable interactions made by Q508 15.
Description and Experimental Characterization of Second-Site Suppressor Designs
Knob-in-to-hole designs—Three designs selected for experimental characterization
were based on the introduction of a bump or hole at the interface that could be
accommodated by pruning back or filling space with neighboring residues. In the first
design (design #1 in Table 1) valine 507 on the GoLoco peptide is mutated to a methionine.
The methionine is predicted to clash with the β-carbon of glutamate 245 from Gαi1 (Figure
1). To accommodate the methionine, two mutations were made to Gαi1, E245L and L249A.
Pruning back residue 249 creates an open space that can be filled by an alternative rotamer
of methionine 507. Switching glutamate 245 to a leucine is primarily isosteric and it does
not relieve any clashes, however, this mutation is predicted to recoup favorable desolvation
energy that is lost by mutating leucine 249 to alanine. Experimentally, this is one of our best
performing designs (Figure 1, Figure S.1, Table 1). V507M weakens binding affinity from
100 nM to just over 1 μM, but when combined with E245L and L249A binding affinity
returns to 50 nM.
The initial destabilizing mutation for the second knob-in-to-hole design (design #2) was
S252L in Gαi1. The new leucine is predicted to clash with L503 from GoLoco. Rosetta
compensated for this mutation with two mutations: L503K on GoLoco and K248E on Gαi1.
K503 is predicted to open up space for L252, and E248 is predicted to form favorable
interactions with K503 (Figure 2). It is interesting that net changes in charge-charge
interactions are not predicted to be the main determinant of altered specificity in this design
(Table 1). This is because R506 on the GoLoco peptide adopts an alternative rotamer in the
redesign (to accommodate K503) and is further from several glutamates on Gαi1.
Experiments indicate that L503K GoLoco rescues S252L, K248E Gαi1 as predicted,
although the initial destabilization with S252L, K248E is modest. S252L, K248E weakens
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Gαi1 binding for GoLoco from 100 nM to 320 nM, and the compensating mutation, L503K,
restores binding to 80 nM (Figure S.2). In these experiments we choose to characterize the
double mutant of Gαi1 (S252L, K248E) with WT GoLoco, and not the single mutant
(S252L), because this is how these molecules would be best used in in vivo suppressor
studies, i.e. destabilizing mutations are made to one partner and then the protein with the
suppressor mutation(s) is tested to determine if it rescues function.
In design #3, L504 on GoLoco is mutated to an alanine creating a hole in the middle of the
interface. Rosetta compensated with L249F and F223V on Gαi1. Experiments indicated that
L504A GoLoco significantly reduced affinity for Gαi1 (Kd = 2.4 μM) but that the
compensating mutations were not successful (Table 1). Because the initial deleterious
mutation was a promising beginning for creating an altered specificity interface, we tested if
we could suppress GoLoco L504A by including additional mutations that are not adjacent to
the initial mutation. In a previous study, we identified several mutations (Q147L, E245L on
Gαi1, and F529W on GoLoco) that enhance the affinity of the GoLoco/Gαi1 interaction 15.
We added three of them to our initial design, creating a designed pair with the sequences
L504A, F529W GoLoco and F223V, L249F, Q147L, E245L Gαi1. None of these mutations
are immediately adjacent to the initial set of mutations (Figure 3a). F529W was expected to
enhance the affinity of L504A GoLoco for wild type Gαi1, but binding remained weak (Kd >
5 μM). The affinity increasing mutations to Gαi1 however, had the desired effect; F223V,
L249F, Q147L, E245L Gαi1 bound L504A, F529W GoLoco with a dissociation constant of
40 nM, thus completely rescuing L504A, F529W GoLoco (Figure 3b). This result indicates
that making use of residues distant from the initial perturbation is an effective way to
rationally design a suppressor. One advantage of this approach is that it is possible to make
use of previous structure-activity studies.
Designs with new hydrogen bonds—Three designs were based on the introduction of
new hydrogen bonds. In each case the initial destabilizing mutation replaced a hydrophobic
amino acid with a polar amino acid. These mutations were predicted to create less favorable
desolvation energies for binding (column labeled Solv – Table 1). In an attempt to recover
from these mutations, Rosetta introduced additional polar amino acids that were predicted to
satisfy the hydrogen bond potential of the first mutation. The rescue mutations were also
predicted to create less favorable desolvation energies for binding, but the prediction was
that the new hydrogen bonds and more favorable Lennard-Jones attractive scores would
counterbalance desolvation penalties. Design #4 starts with the replacement of leucine 519
from GoLoco with a threonine. Despite being within hydrogen bond distance of serine 75 on
Gαi1, this mutation is predicted to be destabilizing because of desolvation costs and less
favorable packing. To suppress L519T Rosetta introduces two mutations: I78S and A111Q.
The complete design results in three new predicted hydrogen bonds: Gαi1 Q111 epsilon
nitrogen with GoLoco T519 gamma oxygen, Gαi1 S78 gamma hydrogen with Gαi1 Q111
epsilon oxygen, and GoLoco T519 gamma oxygen with Gαi1 S75 gamma oxygen. The
geometric parameters for these bonds are within the ranges seen in naturally occurring
proteins 16, however, they are not optimal (Figure 4). Particularly sub-optimal is the donor-
hydrogen-acceptor angle of 115° for Q111 epsilon nitrogen with T519 gamma oxygen. The
experimental results show that the initial mutation is destabilizing, Kd rises from 100 nM to
16 μM, but the rescue mutations do not recover any of the loss in binding (Figure S.3).
In design #5, phenylalanine 63 on UbcH7 was mutated to a histidine and phenylalanine 690
on E6AP was mutated to a tyrosine forming a putative hydrogen bond between the hydroxyl
oxygen on the tyrosine and the epsilon nitrogen of histidine (Figure 5). The new hydrogen
bond was predicted to have favorable geometric parameters (typical values in protein crystal
structures are shown in brackets16): the distance between the hydrogen and oxygen is 1.95
Å (1.7°–2.1°), the angle defined by the donor nitrogen, hydrogen, and acceptor oxygen is
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147° (140°–180°), and the angle defined by the hydrogen, acceptor oxygen and oxygen base
is 127°(100–160). A potential weakness of this design is the lack of a hydrogen partner for
the delta nitrogen of the histidine, which appears to be inaccessible to water in the bound
state. The experimental results for this design are similar to the other designs based on
hydrogen bonding. The initial mutation is destabilizing, the dissociation constant changes
from 5 μM to greater than 50 μM with the F63H mutation, however, the designed rescue
mutation, F690Y, does not recover any binding affinity.
The two previously described hydrogen bond designs (design 4 and 5) make use of polar,
but uncharged side chains. Design #6 is based on the creation of a solvent exposed salt
bridge: V634R E6AP paired with K64E UbcH7. Unlike the previous two designs based on
new hydrogen bonds, the initial mutation in this case, V634R, does not dramatically
destabilize binding (Kd = 11 μM, Kd(wt) = 5 μM). This is probably because R634 is solvent
exposed and therefore there is not a large desolvation penalty for making the mutation. The
suppressor mutation, K64E, does not recover wild type affinity (Kd = 28 μM) (Figure S.4).
This may be because only one of the glutamate oxygens is predicted to hydrogen bond with
634R, while the other is partially removed from solvent.
Replacing polar interactions with hydrophobic interactions—Two designs made
to the UbcH7-E6AP interface make use of polar to non-polar swaps (Figure 6). In both cases
the residues are on the periphery of the interface and are only partially buried. In design #7,
E60L UbcH7 is predicted to weaken binding because of less favorable hydrogen bonding,
solvation energies and electrostatic interactions. T662F and Q661W E6AP compensate by
forming favorable van der Waals contacts as reflected in changes to the Lennard-Jones
score. Experimentally the mutations behave as predicted, although the changes are modest.
E60L UbcH7 reduces binding affinity 3-fold (14 μM) and T662F, Q661W E6AP brings
affinity back to 7 μM (Figure S.5).
In design #8, K96S UbcH7 removes a salt bridge interaction with D641 E6AP. Rosetta
compensates K96S by introducing a lysine at position at 641. We classify this as a polar to
hydrophobic switch because the hydrophobic methylene groups on K641 are predicted to
pack against the methlylene carbon on serine 96 as well as the side chain of proline 97. The
Rosetta solvation score for K96S UbcH7, D641K E6AP is 1.5 kcal/mol more favorable than
the wild type interaction. Experimentally, K96S has a modest effect on binding affinity, but
when combined with D641K there is a large increase in binding affinity, Kd = 100 nM,
providing a 55-fold change in binding specificity (Figure S.6). Given the large change in
specificity, we examined if we could use additional mutations to tune this design to create a
system in which the mutant-wild type pair was destabilized relative to the wild type pair.
Two mutations on the UbcH7 protein that are structurally removed from design #8 were
selected. The first mutation, F63H, from design #5, and the second, A98W, from previous
work14. Adding these two further mutations, F63H and A98W, to K96S weakens binding
with WT E6AP to 100 μM. The rescue mutation, D641K E6AP, brings binding back to 2.5
μM, a 40-fold change in binding specificity (design #8a).
Discussion
Two of the more successful second-site suppressor designs (design #1: 20-fold change in
binding specificity, design #3a: >125-fold change in binding specificity) were based on
knob-in-to-hole designs and used primarily hydrophobic amino acids. In design #3a, we also
used affinity-enhancing mutations distant from the initial destabilization to suppress the
mutant GoLoco sequence. Similar changes in binding specificity have been observed for
other computer-based interface designs that make use of hydrophobic packing10. Sauer and
co-workers redesigned packing at 8 hydrophobic residues at the center of the SspB
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homodimer interface to create a heterodimer that was >100-fold more favorable than the
respective homodimers; although, the heterodimer was significantly destabilized relative to
the wild type homodimer11. Shifman and colleagues have created several calmodulin
variants that switch binding specificity by 20- to 900-fold for target peptides6; 7. These
designs rely primarily on hydrophobic repacking and a small number of charge swaps of
partially exposed charged amino acids.
Our designs that made use of polar to hydrophobic swaps on the periphery of the interface
bound stronger or as tightly as the wild type pair, but the initial ‘perturbing’ mutation did not
dramatically destabilize binding. Serrano and co-workers obtained similar results when
redesigning a PDZ domain to recognize new peptide substrates17. In one case, they swapped
two partially exposed polar residues on the target peptide from polar to hydrophobic. This
had a modest effect on binding to the wild type PDZ domain (5-fold weaker), however,
when they compensated with new hydrophobic residues on the PDZ domain they were able
to increase binding affinity 20-fold. These results are consistent with our previous study that
found that increasing buried hydrophobic surface area at protein-protein interfaces is an
effective strategy for strengthening protein binding affinities15.
Our third set of designs centered on the creation of new hydrogen bonds. A variety of
studies have indicated that buried hydrogen bonds at naturally occurring protein interfaces
can be a strong source of specificity 18; 19. A well-known example of this is a pair of
hydrogen bonding asparagines from the homodimeric coiled-coil GCN420. When the
asparagine is mutated to a leucine the protein no longer forms a specific dimer, but rather
there is an equilibrium between dimers and trimers. Interestingly, however, the thermal
unfolding midpoint for the mutant is 45° higher than the wild type GCN4. It appears that the
main role of the asparagine is to destabilize alternative conformations, not increase the free
energy gap between the folded state and the unfolded state. Is this a general result? Are
buried hydrogen bonds inherently less stabilizing than buried hydrophobic interactions21;
22; 23; 24? This could be one conclusion drawn from our studies. In both cases in which we
attempted to design buried hydrogen bonds, we saw a significant loss in binding affinity.
Similar results have been observed in other design studies that included the creation of
buried hydrogen bonds. Baker and coworkers redesigned the interface between colicin E7
and the immunity protein Im7 to have four new hydrogen bonds25. The binding affinity of
the redesigned pair was several orders of magnitude weaker than the wild type pair. A
crystal structure of the E7-Im7 redesign showed that the hydrogen bonds were forming as
designed, however, their geometric parameters were not ideal. One of the designed hydrogen
bonds had a hydrogen acceptor distance of 3.0 Å (the preferred distance is 2 Å), and all of
the donor-hydrogen-acceptor angles were significantly non-linear (< 150°). Similar
deviations from ideality are present in the models of our designs. In design #4, all three
hydrogen bonds have donor-hydrogen-acceptor angles below 150°. The new hydrogen bond
between a tyrosine and a histidine in design #5 has close to ideal parameters, but there is
only a hydrogen bond partner for one of the histidine nitrogens. When the protein is in the
unbound state, both nitrogens will probably form hydrogen bonds with solvent. These
limitations in the designed hydrogen bonds indicate that the designs may have reduced
binding affinity, not because hydrogen bonds are intrinsically less favorable than
hydrophobic interactions, but rather, because they are sub-optimal hydrogen bonds. There
are many naturally occurring protein-protein interactions in which the key residues for
binding (hot-spot residues) are polar amino acids26.
Creating optimal hydrogen bonds is challenging because not only are hydrogen bonds
dependent on distance and orientation, but most polar amino acids prefer to form multiple
hydrogen bonds. This means that optimizing one hydrogen bond often conflicts with
optimizing others. To examine the sensitivity of design #4 to small backbone perturbations
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we decided to look at the other GoLoco-Gαi1 complex in the asymmetric unit of the crystal
structure. Despite being very similar in structure (the RMSD between residues 78,111, and
519 is 0.2 Å) the redesign has a predicted binding energy that is 1 kcal/mol less favorable
than that obtained with the structure pair used in these studies.
The correlation between the computational and experimental changes in binding energies for
all of the mutations studied here is poor (R2 < 0.1, Table 1, Figure S.7). Contributing to the
poor correlation is the over prediction of steric repulsion and the failure to accurately predict
the energies of buried hydrogen bond networks. Additionally, the creation of an altered
specificity interface may be inherently difficult, i.e. randomly chosen mutations at an
interface are unlikely to have wild type binding affinities. From this perspective, it is
exciting that four of the eight designs maintained wild type or better binding affinities. Of
the ~3000 point mutations computationally tested at the two interfaces, only 40 of the
mutations were predicted to be destabilizing and recoverable via neighboring mutations on
the partner protein. Similar results have been observed when computationally redesigning
protein cores, suggesting there is a restricted set of low energy sequences for a fixed
backbone27. One solution to this constraint from a design and protein evolution perspective
is to also make use of mutations that are non-local to the original specificity changing
mutation. As demonstrated here, these mutations can be used to set baseline affinity, and
therefore, create altered specificity designs with affinities similar to the wild type
proteins25.
In summary, we find that we can most reliably design second-site suppressor mutations that
rely on sterics or the swap of hydrophobic for polar interactions. The design of new
hydrogen bond networks holds promise for creating even more dramatic changes in
specificity, but this may require extensive side chain and backbone optimization to find
conformations that can simultaneously satisfy multiple bonds.
Methods
Rosetta
Second-site suppressor mutations were designed using the molecular modeling program
Rosetta28. Rosetta’s core full atom energy function is a linear sum of molecular mechanics
and knowledge-based terms: a 6–12 Lennard-Jones potential, the Lazaridis-Karplus implicit
solvation model29, an empirically based hydrogen bonding potential16, backbone dependent
rotamer probabilities30, a knowledge-based electrostatics energy potential, amino acid
probabilities based on particular regions of φ/ψ space, and reference energies that
approximate the energies of amino acids in the unfolded state27. Within Rosetta, there are
several variations on this core energy function. For the studies described here, we used a
version of Rosetta with a dampened repulsion potential (command line option, -
soft_rep_design, Rosetta v 2.1). See supplementary material of Dantas et al. for a complete
description of this version of the Rosetta energy function31. It is referred to as
Rosetta_DampRep.
Side chain flexibility is modeled by allowing amino acids to adopt different rotamers. We
use Dunbrack’s backbone dependent rotamer library supplemented with rotamers that vary
chi 1 and chi 2 one standard deviation away from their most probable values30. Low energy
combinations of side chain conformations are identified using Monte Carlo optimization
with simulated annealing.
Computational screening for suppressor mutations
The protein-protein interface was scanned for amino acid point mutations predicted to
destabilize binding (ΔΔGobinding > 0.5 kcal/mol). Residues adjacent to the site of a mutation
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(within 10 Å Cα-Cα distance) were repacked with Rosetta’s side chain optimization protocol
to best accommodate the mutation27. Binding energies were calculated by subtracting the
energy of the complex from the energies of the individual chains. Any residues that were
repacked in the mutant complex were also repacked in the wild type complex.
For each destabilizing point mutation a sequence optimization simulation was performed to
search for compensating mutations, residues with any atom within 5.5 Å of the point mutant
were allowed to switch identity 27. Residues on both sides of the interface were allowed to
change identity during this process. A bonus energy of −0.6 kcal/mol was given to the wild
type neighbors during these simulations in order to favor designs that had small numbers of
mutations. Residues within 10 Å of any of the mutated residues were repacked during the
binding energy calculations. The resulting second-site suppressor designs were then
evaluated by comparing the predicted binding energy for the design with the predicted
binding energy of the wild-type complex. Designs with predicted binding energies equal to
or less than 0.3 kcal/mol were considered, indicating the designs were predicted to achieve
binding affinities similar to that of the wild-type complexes. Designs were not considered
for experimental studies if the mutations destabilized either of the individual proteins by
more than 1 kcal/mol.
Designs—The atomic coordinates for Gαi1 complexed with the GoLoco motif from
RGS14 are taken from the crystal structure PDB 2OM214. Designs containing mutations on
sequence positions of Gαi1 or the GoLoco motif identified as important for binding GDP or
Magnesium were not considered12, 32. These sequence positions for Gαi1 were the
following: K46, S47, T181, V179, D200, G203. These sequence positions for the GoLoco
motif were the following: D514, Q515 and R516. Additionally, designs containing
mutations in the Switch II region of Gαi1 and interfaced with the GoLoco motif were not
excluded but were avoided. These sequence positions were the following: D200-R208. The
atomic coordinates for UbcH7 complexed with E6AP are taken from the crystal structure
PDB 1C4Z13.
Construction and cloning of protein designs
We used the GoLoco motif of RGS14 (residues 496–531) expressed as a fusion to Tenascin
as previously described15. We used the N-terminal-truncated, hexahistidine-tagged
expression construct of human Gαi1 with the first 25 codons of the Gα open reading frame
removed, as previously described13. The UbcH7 and E6AP expression plasmids have been
previously described33. Point mutations were introduced using the QuickChange® site-
directed mutagenesis protocol (Stratagene) and all vectors were verified by DNA
sequencing.
Protein Production
The GoLoco motif peptide and Gαi1 were expressed as previously described15. E6AP and
UbcH7 were expressed and purified as previously described33. For both systems, gel
filtration was used to make sure the proteins remained monomeric after redesign. Protein
concentrations were determined by measuring absorbance at 280 nm. Extinction coefficients
were calculated using the method described by Gill and von Hipple34.
Fluorescence polarization binding analysis
The thiol-reactive fluorescent probe 6-IAF (Molecular Probes) was conjugated to the unique
cysteine on the GoLoco motif as previously described15. Fluorescence polarization assays
were carried out on a Jobin Yvon Horiba Spec FluoroLog-3 instrument (Jobin Yvon Inc.)
performed in L-format with the excitation wavelength set at 495 nm and the emission
wavelength set at 520 nm. Binding assays were performed with the GoLoco motif diluted to
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between 50 nM and 100 nM and the excitation and emission slit widths adjusted to give a
fluorescence intensity >100,000 counts per second. Data were analyzed using a model for
single site binding according to equation (1), which was incorporated into equation (2) to
account for the observed polarization:
(1)
(2)
Where [A:B] is the concentration of fluorescein-GoLoco motif protein and Gαi1 complex
formed, [At} is the total concentration of fluorescein-GoLoco motif protein, [Bt] is the
concentration of Gαi1, Pmax is the maximum polarization observed when all fluorescein-
GoLoco motif protein is bound to Gαi1, and Pobs is the measured polarization at a given
concentration of Gαi1. The data were fit according to equation (2) using non-linear
regression with SigmaPlot software to obtain fitted parameters for Kd, Pmax, and Po.
The fluorophore bodipy (507/545)-iodoacetamide (Molecular Probes) was conjugated to
UbcH7 as previously described33. Binding assays were performed as previously
described33.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Models of a steric switch designed at the Gαi1 (green) and GoLoco (blue) interface (design
#1). A) Wild type interface. B) The mutation V507M is predicted to create a clash at the
interface that is accommodated by L249A (panel C). D) Binding curves as measured by
fluorescence polarization, Gαi1 was titrated into GoLoco labeled with fluorescein.
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Models of a steric switch designed at the Gαi1 – GoLoco interface (design #2). A) Wild type
interface. B) The mutations S252L and K248E are predicted to create a clash at the interface
between L503 and L252 that is accommodated by L503K (panel C). The predicted
contribution of electrostatics to binding energy is reduced in the final design by
rearrangement of R506 to accommodate K503.
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Using residues distant from the initial mutation to create a second-site suppressor. A)
Mutations in the initial design (design #3) F223V, L249F Gαi1: L504A GoLoco are shown
in red. This design pair has reduced affinity compared to the wild type pair (~5 μM
compared to 0.1 μM). Addition of affinity enhancing mutations, Q147L-Gαi1, E245L-Gαi1
and F529W-GoLoco (shown in blue) creates a suppressible system. B) L504A, F529W
GoLoco bind WT Gαi1 weakly (Kd ~ 5 μM), but has strong affinity for F223V, L249F,
Q147L, E245L Gαi1 (Kd = 0.04 μM).
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Design of a non-polar to polar switch at the GoLoco (blue) and Gαi1 (green) interface
(design #4). A) Wild type interface. B) Destabilizing mutation L519T. C) Mutations
designed to compensate for L519T, A111Q and I78S. D) Hydrogen bond parameters for the
redesigned residues.
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Design of a non-polar to polar switch at the UbcH7 (purple) and E6AP interface (yellow)
(design #5). A) Wild type interface. B) F63H is predicted to create a buried polar atom that
can be accommodated by forming a hydrogen bond with a tyrosine introduced at residue 690
of E6AP (panel C). D) Binding experiments indicate that F690Y does not rescue binding.
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Design of two polar to non-polar switches at the interface of E6AP (yellow) and UbcH7
(purple). Panels A–C: the mutation E60L is compensated with T662F and Q661W (design
#7). Panels D–F: the mutation K96S is compensated with D641K (design #8). Despite only
involving polar amino acids, design #8 is classified as polar to non-polar because a salt
bridge interaction in the WT (K96 with D641) is replaced with hydrophobic interactions
between the methylene groups on K641, the beta carbon of S96 and the side chain of proline
97.
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